AR074398A1 - Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa - Google Patents
Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso paInfo
- Publication number
- AR074398A1 AR074398A1 ARP090104529A ARP090104529A AR074398A1 AR 074398 A1 AR074398 A1 AR 074398A1 AR P090104529 A ARP090104529 A AR P090104529A AR P090104529 A ARP090104529 A AR P090104529A AR 074398 A1 AR074398 A1 AR 074398A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- composition
- fragment
- monoclonal antibody
- anemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpo monoclonal o su fragmento de unión a antígeno que une ferroportina humana 1, que consiste de la secuencia de aminoácido mostrada en SEQ ID NO: 1 y al menos un fragmento de péptido del mismo seleccionado del grupo que consta de SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, y SEQ ID NO: 95 y comprende una LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que comprenden la secuencia de aminoácido mostrada en SEQ ID NOS: 37, 129, 22, 107, 118, y 120, respectivamente. Inhiben la actividad de FPN1 humana y son efectivos en mantener o incrementar el transporte de hierro fuera de células mamíferas y/o mantienen o incrementan el nivel de hierro en suero, conteo de reticulocitos, conteo de glóbulos rojos, hemoglobina, y/o hematocrito en un sujeto in vivo. Polinucleótido que comprende una secuencia de nucleótidos que codifica dicho anticuerpo monoclonal o fragmento de unión a antígeno. Vector de expresión recombinante que comprende dicho polinucleótido. Célula huésped transformada por dicho vector de expresión. Su uso para la preparación de un medicamento útil para el tratamiento o prevención de anemia. Composición farmacéutica que comprende dicho anticuerpo monoclonal o fragmento. Proceso para producir dicho anticuerpo monoclonal o fragmento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074398A1 true AR074398A1 (es) | 2011-01-12 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104529A AR074398A1 (es) | 2008-12-05 | 2009-11-24 | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (es) |
| JP (1) | JP5713917B2 (es) |
| KR (1) | KR101353117B1 (es) |
| CN (1) | CN102238962B (es) |
| AR (1) | AR074398A1 (es) |
| AU (1) | AU2009322587B2 (es) |
| BR (1) | BRPI0922288A2 (es) |
| CA (1) | CA2745618C (es) |
| CY (1) | CY1117355T1 (es) |
| DK (1) | DK2373335T3 (es) |
| EA (1) | EA020472B1 (es) |
| ES (1) | ES2566343T3 (es) |
| HK (1) | HK1158977A1 (es) |
| HR (1) | HRP20160302T1 (es) |
| HU (1) | HUE028585T2 (es) |
| IL (1) | IL212731A0 (es) |
| MX (1) | MX2011005939A (es) |
| NZ (1) | NZ592545A (es) |
| PA (1) | PA8849601A1 (es) |
| PL (1) | PL2373335T3 (es) |
| SG (1) | SG171960A1 (es) |
| SI (1) | SI2373335T1 (es) |
| TW (1) | TW201023891A (es) |
| UA (1) | UA104741C2 (es) |
| WO (1) | WO2010065496A1 (es) |
| ZA (1) | ZA201103941B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150013277A (ko) * | 2012-05-14 | 2015-02-04 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) * | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| ES2500066T3 (es) * | 2008-01-25 | 2014-09-30 | Amgen, Inc | Anticuerpos frente a ferroportina y métodos de uso |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active IP Right Cessation
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en active Application Filing
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
- 2011-12-20 HK HK11113719.0A patent/HK1158977A1/zh not_active IP Right Cessation
-
2016
- 2016-03-23 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE028585T2 (en) | 2016-12-28 |
| SI2373335T1 (sl) | 2016-04-29 |
| KR20110084996A (ko) | 2011-07-26 |
| JP5713917B2 (ja) | 2015-05-07 |
| TW201023891A (en) | 2010-07-01 |
| EA201170764A1 (ru) | 2011-12-30 |
| HRP20160302T1 (hr) | 2016-04-22 |
| CY1117355T1 (el) | 2017-04-26 |
| PL2373335T3 (pl) | 2016-08-31 |
| KR101353117B1 (ko) | 2014-02-17 |
| JP2012510814A (ja) | 2012-05-17 |
| PA8849601A1 (es) | 2010-07-27 |
| EA020472B1 (ru) | 2014-11-28 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| EP2373335B1 (en) | 2016-02-24 |
| CA2745618C (en) | 2014-06-10 |
| WO2010065496A1 (en) | 2010-06-10 |
| NZ592545A (en) | 2012-12-21 |
| DK2373335T3 (en) | 2016-05-02 |
| SG171960A1 (en) | 2011-07-28 |
| EP2373335A1 (en) | 2011-10-12 |
| CN102238962A (zh) | 2011-11-09 |
| ZA201103941B (en) | 2012-11-28 |
| AU2009322587A1 (en) | 2011-07-28 |
| CA2745618A1 (en) | 2010-06-10 |
| CN102238962B (zh) | 2014-02-12 |
| HK1158977A1 (zh) | 2012-07-27 |
| UA104741C2 (uk) | 2014-03-11 |
| IL212731A0 (en) | 2011-07-31 |
| ES2566343T3 (es) | 2016-04-12 |
| AU2009322587B2 (en) | 2013-09-26 |
| MX2011005939A (es) | 2011-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| JP6865778B2 (ja) | 癌幹細胞を含む癌の診断および治療法 | |
| CA2983293C (en) | Modulators of ror1-ror2 binding | |
| JP2023088925A (ja) | Ｐｓｇｌ－１アンタゴニスト及びその使用 | |
| PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| JP2013504589A5 (es) | ||
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| TW201444866A (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| JP2012100677A5 (es) | ||
| AR072039A1 (es) | Anticuerpos contra el virus de la hepatitis c | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| AR073442A1 (es) | Metodos para tratar cancer y composicion o equipo que comprende un anticuerpo l2g7 humanizado | |
| JP2021534757A (ja) | アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| CA2793647A1 (en) | Prophylaxis of colorectal and gastrointestinal cancer | |
| PH12014501613B1 (en) | Anti-asic1 antibodies and uses thereof | |
| AR084627A1 (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |